Janus kinase (JAK) inhibitors have emerged as an important treatment option, offering rapid and targeted immunomodulation.1 However, in 2019, regulatory agencies modified the label for JAK inhibitors based on the ORAL Surveillance trial.2 The noninferiority ORAL Surveillance trial compared the safety of tofacitinib (5 mg or 10 mg twice daily) vs tumor necrosis factor (TNF)-α antagonists in patients with rheumatoid arthritis (RA) who were aged 50 years or older and had at least 1 additional cardiovascular risk factor. The gene discussed is TNF; the disease is rheumatoid arthritis.